A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Replimune Group, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 9,200 shares of REPL stock, worth $100,372. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,200
Previous 18,200 49.45%
Holding current value
$100,372
Previous $148,000 44.59%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.01 - $9.46 $738,704 - $1.39 Million
147,446 Added 218.63%
214,886 $1.93 Million
Q1 2024

May 15, 2024

SELL
$6.87 - $9.31 $962,466 - $1.3 Million
-140,097 Reduced 67.5%
67,440 $550,000
Q4 2023

Feb 14, 2024

SELL
$6.75 - $16.18 $6.68 Million - $16 Million
-989,498 Reduced 82.66%
207,537 $1.75 Million
Q3 2023

Nov 14, 2023

BUY
$15.96 - $22.18 $972,235 - $1.35 Million
60,917 Added 5.36%
1,197,035 $20.5 Million
Q2 2023

Aug 14, 2023

BUY
$15.65 - $24.1 $331,873 - $511,064
21,206 Added 1.9%
1,136,118 $26.4 Million
Q1 2023

May 15, 2023

BUY
$17.48 - $29.09 $9.77 Million - $16.3 Million
558,936 Added 100.53%
1,114,912 $19.7 Million
Q4 2022

Feb 14, 2023

SELL
$17.09 - $27.91 $1.54 Million - $2.51 Million
-90,047 Reduced 13.94%
555,976 $15.1 Million
Q3 2022

Nov 14, 2022

BUY
$15.6 - $21.15 $978,213 - $1.33 Million
62,706 Added 10.75%
646,023 $11.2 Million
Q2 2022

Aug 15, 2022

BUY
$13.32 - $19.98 $3.27 Million - $4.9 Million
245,262 Added 72.55%
583,317 $10.2 Million
Q1 2022

May 16, 2022

SELL
$15.24 - $29.75 $2 Million - $3.91 Million
-131,530 Reduced 28.01%
338,055 $5.74 Million
Q4 2021

Feb 14, 2022

BUY
$25.43 - $34.25 $2.27 Million - $3.06 Million
89,350 Added 23.5%
469,585 $12.7 Million
Q3 2021

Nov 15, 2021

SELL
$28.98 - $39.54 $325,764 - $444,469
-11,241 Reduced 2.87%
380,235 $11.3 Million
Q2 2021

Aug 16, 2021

SELL
$28.5 - $39.37 $9.77 Million - $13.5 Million
-342,821 Reduced 46.69%
391,476 $15 Million
Q1 2021

May 17, 2021

SELL
$30.22 - $45.57 $13 Million - $19.6 Million
-430,202 Reduced 36.94%
734,297 $22.4 Million
Q4 2020

Feb 16, 2021

BUY
$23.5 - $52.65 $16.8 Million - $37.6 Million
714,087 Added 158.54%
1,164,499 $44.4 Million
Q3 2020

Nov 16, 2020

SELL
$18.85 - $27.0 $43,336 - $62,073
-2,299 Reduced 0.51%
450,412 $10.4 Million
Q2 2020

Aug 14, 2020

SELL
$9.76 - $25.95 $382,269 - $1.02 Million
-39,167 Reduced 7.96%
452,711 $11.3 Million
Q1 2020

May 15, 2020

SELL
$8.9 - $19.08 $316,163 - $677,797
-35,524 Reduced 6.74%
491,878 $4.9 Million
Q4 2019

Feb 14, 2020

BUY
$11.61 - $17.21 $3.86 Million - $5.72 Million
332,486 Added 170.58%
527,402 $7.57 Million
Q3 2019

Nov 14, 2019

BUY
$10.01 - $16.87 $86,436 - $145,672
8,635 Added 4.64%
194,916 $2.71 Million
Q2 2019

Aug 14, 2019

BUY
$12.51 - $17.28 $125,212 - $172,955
10,009 Added 5.68%
186,281 $2.73 Million
Q1 2019

May 15, 2019

SELL
$10.26 - $16.24 $579,515 - $917,283
-56,483 Reduced 24.27%
176,272 $0
Q4 2018

Feb 14, 2019

SELL
$9.97 - $15.57 $1.56 Million - $2.44 Million
-156,780 Reduced 40.25%
232,755 $2.33 Million
Q3 2018

Nov 13, 2018

BUY
$14.99 - $22.14 $5.84 Million - $8.62 Million
389,535 New
389,535 $0

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $538M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.